Authentification abonné
lvrea
Accueil Tous les numéros Volume 27 / Numéro 4 (Juillet 2018) Méd. Intensive Réa., 27 4 (2018) 372-380 Références
Accès gratuit
Numéro
Méd. Intensive Réa.
Volume 27, Numéro 4, Juillet 2018
Médecine interne et transversalité
Page(s) 372 - 380
Section Mise au point / Update
DOI https://doi.org/10.3166/rea-2018-0058
Publié en ligne 29 août 2018
  • Tamma PD, Goodman KE, Harris AD, Tekle T, Roberts A, Taiwo A, Simner PJ, (2017) Comparing the outcomes of patients with carbapenemase-producing and non-carbapenemase-producing carbapenem-resistant Enterobacteriaceae bacteremia. Clin Infect Dis 64: 257–264 [CrossRef] [PubMed] [Google Scholar]
  • Kassis-Chikhani N, Saliba F, Carbonne A, Neuville S, Decre D, Sengelin C, Guerin C, Gastiaburu N, Lavigne-Kriaa A, Boutelier C, Arlet G, Samuel D, Castaing D, Dussaix E, Jarlier V, (2010) Extended measures for controlling an outbreak of VIM-1 producing imipenem-resistant Klebsiella pneumoniae in a liver transplant centre in France, 2003–2004. Euro Surveill 15: 19713 [CrossRef] [PubMed] [Google Scholar]
  • http://invs.santepubliquefrance.fr/Dossiers-thematiques/Maladies-infectieuses/Infections-associees-aux-soins/Surveillance-des-infections-associees-aux-soins-IAS/Enterobacteries-productrices-de-carbapenemases-EPC/Episodes-impliquant-des-EPC-en-France.-Situation-epidemiologique-du-31-decembre-2015 [Google Scholar]
  • Société Française de Microbiologie tableaux des concentrations critiques pour l’interprétation des CMI et des diamètres des zones d’inhibition. In : CASFM : EUCAST : Société Française de Microbiologie Ed ; 2017 : 38 [Google Scholar]
  • Daikos GL, Markogiannakis A, (2011) Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? Clin Microbiol Infect 17: 1135–1141 [CrossRef] [PubMed] [Google Scholar]
  • Tumbarello M, Viale P, Viscoli C, Trecarichi EM, Tumietto F, Marchese A, Spanu T, Ambretti S, Ginocchio F, Cristini F, Losito AR, Tedeschi S, Cauda R, Bassetti M, (2012) Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 55: 943–950 [CrossRef] [PubMed] [Google Scholar]
  • Tzouvelekis LS, Markogiannakis A, Piperaki E, Souli M, Daikos GL, (2014) Treating infections caused by carbapenemase-producing Enterobacteriaceae. Clin Microbiol Infect 20: 862–872 [CrossRef] [PubMed] [Google Scholar]
  • Daikos GL, Tsaousi S, Tzouvelekis LS, Anyfantis I, Psichogiou M, Argyropoulou A, Stefanou I, Sypsa V, Miriagou V, Nepka M, Georgiadou S, Markogiannakis A, Goukos D, Skoutelis A, (2014) Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 58: 2322–2328 [CrossRef] [PubMed] [Google Scholar]
  • Tumbarello M, Trecarichi EM, De Rosa FG, Giannella M, Giacobbe DR, Bassetti M, Losito AR, Bartoletti M, Del Bono V, Corcione S, Maiuro G, Tedeschi S, Celani L, Cardellino CS, Spanu T, Marchese A, Ambretti S, Cauda R, Viscoli C, Viale P; ISGRI-SITA (Italian Study Group on Resistant Infections of the Società Italiana Terapia Antinfettiva), (2015) Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother 70: 2133–2143 [CrossRef] [PubMed] [Google Scholar]
  • Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL, (2012) Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev 25: 682–707 [PubMed] [Google Scholar]
  • Cattoir V, (2014) Traitement des infections dues à entérobactéries productrices de carbapénémases. J Anti Infect 16: 99–105 [CrossRef] [Google Scholar]
  • Wiskirchen DE, Crandon JL, Nicolau DP, (2013) Impact of various conditions on the efficacy of dual carbapenem therapy against KPC-producing Klebsiella pneumoniae . Int J Antimicrob Agents 41: 582–585 [CrossRef] [PubMed] [Google Scholar]
  • Giamarellou H, Galani L, Baziaka F, Karaiskos I, (2013) Effectiveness of a double-carbapenem regimen for infections in humans due to carbapenemase-producing pandrug-resistant Klebsiella pneumoniae . Antimicrob Agents Chemother 57: 2388–2390 [CrossRef] [PubMed] [Google Scholar]
  • Oliva A, D’Abramo A, D’Agostino C, Iannetta M, Mascellino MT, Gallinelli C, Mastroianni CM, Vullo V, (2014) Synergistic activity and effectiveness of a double-carbapenem regimen in pandrug-resistant Klebsiella pneumoniae bloodstream infections. J Antimicrob Chemother 69: 1718–1720 [CrossRef] [PubMed] [Google Scholar]
  • Poirel L, Kieffer N, Nordmann P, (2016) In vitro evaluation of dual carbapenem combinations against carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother 71: 156–161 [CrossRef] [PubMed] [Google Scholar]
  • Cprek JB, Gallagher JC, (2015) Ertapenem-containing double-carbapenem therapy for treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae . Antimicrob Agents Chemother 60: 669–673 [CrossRef] [PubMed] [Google Scholar]
  • Bassetti M, Peghin M, Pecori D, (2016) The management of multidrug-resistant Enterobacteriaceae. Curr Opin Infect Dis 29: 583–594 [CrossRef] [PubMed] [Google Scholar]
  • Plachouras D, Karvanen M, Friberg LE, Papadomichelakis E, Antoniadou A, Tsangaris I, Karaiskos I, Poulakou G, Kontopidou F, Armaganidis A, Cars O, Giamarellou H, (2009) Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 53: 3430–3436 [CrossRef] [PubMed] [Google Scholar]
  • Rocco M, Montini L, Alessandri E, Venditti M, Laderchi A, De Pascale G, Raponi GG, Vitale M, Pietropaoli P, Antonelli M, (2013) Risk factors for acute kidney injury in critically ill patients receiving high intravenous doses of colistin methanesulfonate and/or other nephrotoxic antibiotics: a retrospective cohort study. Crit Care 17: R174 [CrossRef] [PubMed] [Google Scholar]
  • Kim J, Lee KH, Yoo S, Pai H, (2009) Clinical characteristics and risk factors of colistin-induced nephrotoxicity. Int J Antimicrob Agents 34: 434–438 [CrossRef] [PubMed] [Google Scholar]
  • Giacobbe DR, Del Bono V, Trecarichi EM, De Rosa FG, Giannella M, Bassetti M, Bartoloni A, Losito AR, Corcione S, Bartoletti M, Mantengoli E, Saffioti C, Pagani N, Tedeschi S, Spanu T, Rossolini GM, Marchese A, Ambretti S, Cauda R, Viale P, Viscoli C, Tumbarello M; ISGRI-SITA (Italian Study Group on Resistant Infections of the Società Italiana Terapia Antinfettiva), (2015) Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: results from a multicenter case-control-control study. Clin Microbiol Infect 2: 1106.e1–1106.e8 [CrossRef] [Google Scholar]
  • Wright MS, Suzuki Y, Jones MB, Marshall SH, Rudin SD, Van Duin D, Kaye K, Jacobs MR, Bonomo RA, Adams MD, (2015) Genomic and transcriptomic analyses of colistin-resistant clinical isolates of Klebsiella pneumoniae reveal multiple pathways of resistance. Antimicrob Agents Chemother 59: 536–543 [CrossRef] [PubMed] [Google Scholar]
  • Mohamed AF, Karaiskos I, Plachouras D, Karvanen M, Pontikis K, Jansson B, Papadomichelakis E, Antoniadou A, Giamarellou H, Armaganidis A, Cars O, Friberg LE, (2012) Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother 56: 4241–4249 [CrossRef] [PubMed] [Google Scholar]
  • Dalfino L, Puntillo F, Mosca A, Monno R, Spada ML, Coppolecchia S, Miragliotta G, Bruno F, Brienza N, (2012) High-dose, extended-interval colistin administration in critically ill patients: is this the right dosing strategy? A preliminary study. Clin Infect Dis 54: 1720–1726 [CrossRef] [PubMed] [Google Scholar]
  • Florescu DF, Qiu F, McCartan MA, Mindru C, Fey PD, Kalil AC, (2012) What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression. Clin Infect Dis 54: 670–680 [CrossRef] [PubMed] [Google Scholar]
  • Tascini C, Tagliaferri E, Giani T, Leonildi A, Flammini S, Casini B, Lewis R, Ferranti S, Rossolini GM, Menichetti F, (2013) Synergistic activity of colistin plus rifampin against colistin-resistant KPC-producing Klebsiella pneumoniae . Antimicrob Agents Chemother 57: 3990–3993 [CrossRef] [PubMed] [Google Scholar]
  • Forrest GN, Tamura K, (2010) Rifampin combination therapy for non mycobacterial infections. Clin Microbiol Rev 23: 14–34 [CrossRef] [PubMed] [Google Scholar]
  • Sader HS, Castanheira M, Flamm RK, Mendes RE, Farrell DJ, Jones RN, (2015) Tigecycline activity tested against carbapenem-resistant Enterobacteriaceae from 18 European nations: results from the SENTRY surveillance program (2010–2013). Diagn Microbiol Infect Dis 83: 183–186 [CrossRef] [Google Scholar]
  • Ceccarelli G, Falcone M, Giordano A, Mezzatesta ML, Caio C, Stefani S, Venditti M, (2013) Successful ertapenem–doripenem combination treatment of bacteremic ventilator-associated Pneumonia due to colistin-resistant KPC-producing Klebsiella pneumoniae . Antimicrob Agents Chemother 57: 2900–2901 [CrossRef] [PubMed] [Google Scholar]
  • Freire AT, Melnyk V, Kim MJ, Datsenko O, Dzyublik O, Glumcher F, Chuang YC, Maroko RT, Dukart G, Cooper CA, Korth-Bradley JM, Dartois N, Gandjini H, (2010) Comparison of tigecycline withimipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 68: 140–151 [CrossRef] [Google Scholar]
  • Poulakou G, Kontopidou FV, Paramythiotou E, Kompoti M, Katsiari M, Mainas E, Nicolaou C, Yphantis D, Antoniadou A, Trikka-Graphakos E, Roussou Z, Clouva P, Maguina N, Kanellakopoulou K, Armaganidis A, Giamarellou H, (2009) Tigecycline in the treatment of infections from multidrug resistant gram-negative pathogens. J Infect 58: 273–284 [CrossRef] [PubMed] [Google Scholar]
  • Ramirez J, Dartois N, Gandjini H, Yan JL, Korth-Bradley J, McGover PC, (2013) Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenemcilastatin for treatment of hospital acquired Pneumonia. Antimicrob Agents Chemother 57: 1756–1762 [CrossRef] [PubMed] [Google Scholar]
  • Sbrana F, Malacarne P, Viaggi B, Costanzo S, Leonetti P, Leonildi A, Casini B, Tascini C, Menichetti F, (2013) Carbapenem-sparing antibiotic regimens for infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae in intensive care unit. Clin Infect Dis 56: 697–700 [CrossRef] [PubMed] [Google Scholar]
  • Raz R, (2012) Fosfomycin: an old–new antibiotic. Clin Microbiol Infect 18: 4–7 [CrossRef] [PubMed] [Google Scholar]
  • Vardakas KZ, Legakis NJ, Triarides N, Falagas ME, (2016) Susceptibility of contemporary isolates to fosfomycin: a systematic review of the literature. Int J Antimicrob Agents 47: 269–285 [CrossRef] [PubMed] [Google Scholar]
  • Albiero J, Sy SK, Mazucheli J, Caparroz-Assef SM, Costa BB, Alves JL, Gales AC, Tognim MC, (2016) Pharmacodynamic evaluation of the potential clinical utility of fosfomycin and meropenem in combination therapy against KPC-2-producing Klebsiella pneumoniae . Antimicrob Agents Chemother 60: 4128–4139 [CrossRef] [PubMed] [Google Scholar]
  • Rizek C, Ferraz JR, van der Heijden IM, Giudice M, Mostachio AK, Paez J, Carrilho C, Levin AS, Costa SF, (2015) In vitro activity of potential old and new drugs against multidrug-resistant gram-negatives. J Infect Chemother 21: 114–117 [CrossRef] [Google Scholar]
  • Pontikis K, Karaiskos I, Bastani S, Dimopoulos G, Kalogirou M, Katsiari M, Oikonomou A, Poulakou G, Roilides E, Giamarellou H, (2014) Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. Int J Antimicrob Agents 43: 52–59 [CrossRef] [PubMed] [Google Scholar]
  • Gonzalez-Padilla M, Torre-Cisneros J, Rivera-Espinar F, Pontes-Moreno A, López-Cerero L, Pascual A, Natera C, Rodríguez M, Salcedo I, Rodríguez-López F, Rivero A, Rodríguez-Baño J, (2015) Gentamicin therapy for sepsis due to carbapenem-resistant and colistin-resistant Klebsiella pneumoniae . J Antimicrob Chemother 70: 905–913 [CrossRef] [PubMed] [Google Scholar]
  • Morin JP, Olier B, Viotte G, Fillastre JP, (1984) Can fosfomycin reduce the nephrotoxicity of aminoglycosides? Pathol Biol 32: 338–342 [PubMed] [Google Scholar]
  • Doi Y, Paterson DL, (2015) Carbapenemase-producing Enterobacteriaceae. Semin Respir Crit Care Med 36: 74–84 [CrossRef] [PubMed] [Google Scholar]
  • Qureshi ZA, Paterson DL, Potoski BA, Kilayko MC, Sandovsky G, Sordillo E, Polsky B, Adams-Haduch JM, Doi Y, (2012) Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 56: 2108–2113 [CrossRef] [PubMed] [Google Scholar]
  • Falagas ME, Lourida P, Poulikakos P, Rafailidis PI, Tansarli GS, (2014) Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob Agents Chemother 58: 654–663 [CrossRef] [PubMed] [Google Scholar]
  • Lee GC, Burgess DS, (2012) Treatment of Klebsiella pneumoniae carbapenemase (KPC) infections: a review of published case series and case reports. Ann Clin Microbiol Antimicrob 11: 32 [CrossRef] [PubMed] [Google Scholar]
  • Paul M, Carmeli Y, Durante-Mangoni E, Mouton JW, Tacconelli E, Theuretzbacher U, Mussini C, Leibovici L, (2014) Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother 69: 2305–2309 [CrossRef] [PubMed] [Google Scholar]
  • Dickstein Y, Leibovici L, Yahav D, Eliakim-Raz N, Daikos GL, Skiada A, Antoniadou A, Carmeli Y, Nutman A, Levi I, Adler A, Durante-Mangoni E, Andini R, Cavezza G, Mouton JW, Wijma RA, Theuretzbacher U, Friberg LE, Kristoffersson AN, Zusman O, Koppel F, Benattar YD, Altunin S, Paul M; The AIDA Consortium, (2016) Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol. BMJ Open 6: e009956 [CrossRef] [PubMed] [Google Scholar]
  • Fredborg M, Sondergaard TE, Wang M, (2017) Synergistic activities of meropenem double and triple combinations against carbapenemase-producing Enterobacteriaceae. Diagn Microbiol Infect Dis 88: 355–360 [CrossRef] [Google Scholar]
  • Torres A, Zhong N, Pachl J, Timsit JF, Kollef M, Chen Z, Song J, Taylor D, Laud PJ, Stone GG, Chow JW, (2018) Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis 18: 285–295 [CrossRef] [PubMed] [Google Scholar]
  • Carmeli Y, Armstrong J, Laud PJ, Newell P, Stone G, Wardman A, Gasink LB, (2016) Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study. Lancet Infect Dis 16: 661–673 [CrossRef] [PubMed] [Google Scholar]
  • Mazuski JE, Gasink LB, Armstrong J, Broadhurst H, Stone GG, Rank D, Llorens L, Newell P, Pachl J, (2016) Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program. Clin Infect Dis 62: 1380–1389 [CrossRef] [PubMed] [Google Scholar]
  • Wagenlehner FM, Sobel JD, Newell P, Armstrong J, Huang X, Stone GG, Yates K, Gasink LB, (2016) Ceftazidime-avibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program. Clin Infect Dis 63: 754–762 [CrossRef] [PubMed] [Google Scholar]
  • de Jonge BL, Karlowsky JA, Kazmierczak KM, Biedenbach DJ, Sahm DF, Nichols WW, (2016) In vitro susceptibility to ceftazidime-avibactam of carbapenem-nonsusceptible Enterobacteriaceae isolates collected during the INFORM global surveillance study (2012 to 2014). Antimicrob Agents Chemother 60: 3163–3169 [CrossRef] [PubMed] [Google Scholar]
  • Shields RK, Nguyen MH, Chen L, Press EG, Potoski BA, Marini RV, Doi Y, Kreiswirth BN, Clancy CJ, (2017) Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother 61(8): e00883–17 [PubMed] [Google Scholar]
  • Shields RK, Potoski BA, Haidar G, Hao B, Doi Y, Chen L, Press EG, Kreiswirth BN, Clancy CJ, Nguyen MH, (2016) Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis 63: 1615–1618 [CrossRef] [PubMed] [Google Scholar]
  • van Duin D, Lok JJ, Earley M, Cober E, Richter SS, Perez F, Salata RA, Kalayjian RC, Watkins RR, Doi Y, Kaye KS, Fowler VG Jr, Paterson DL, Bonomo RA, Evans S; Antibacterial Resistance Leadership Group, (2018) Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae. Clinical Infect Dis 66: 163–171 [CrossRef] [Google Scholar]
  • Temkin E, Torre-Cisneros J, Beovic B, Benito N, Giannella M, Gilarranz R, Jeremiah C, Loeches B, Machuca I, Jiménez-Martín MJ, Martínez JA, Mora-Rillo M, Navas E, Osthoff M, Pozo JC, Ramos JC, Rodriguez M, Sánchez-García M, Viale P, Wolff M, Carmeli Y, (2017) Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms. Antimicrob Agents Chemother 61(2): e01964–16 [PubMed] [Google Scholar]
  • Gugliandolo A, Caio C, Mezzatesta ML, Rifici C, Bramanti P, Stefani S, Mazzon E, (2017) Successful ceftazidime-avibactam treatment of MDR-KPC-positive Klebsiella pneumoniae infection in a patient with traumatic brain injury: a case report. Medicine 96: e7664 [CrossRef] [PubMed] [Google Scholar]
  • Davido B, Fellous L, Lawrence C, Maxime V, Rottman M, Dinh A, (2017) Ceftazidime-avibactam and aztreonam, an interesting strategy to overcome β-lactam resistance conferred by metallo-β-lactamases in Enterobacteriaceae and Pseudomonas aeruginosa . Antimicrob Agents Chemother 61: e01008–17 [CrossRef] [PubMed] [Google Scholar]
  • Marshall S, Hujer AM, Rojas LJ, Papp-Wallace KM, Humphries RM, Spellberg B, Hujer KM, Marshall EK, Rudin SD, Perez F, Wilson BM, Wasserman RB, Chikowski L, Paterson DL, Vila AJ, van Duin D, Kreiswirth BN, Chambers HF, Fowler VG Jr, Jacobs MR, Pulse ME, Weiss WJ, Bonomo RA, (2017) Can ceftazidime-avibactam and aztreonam overcome β-lactam resistance conferred by metallo-β-lactamases in Enterobacteriaceae? Antimicrob Agents Chemother 61(4): e02243–16 [CrossRef] [PubMed] [Google Scholar]
  • Bowers DR, Huang V, (2016) Emerging issues and treatment strategies in carbapenem-resistant Enterobacteriaceae (CRE). Curr Infect Dis Rep 18: 48 [CrossRef] [PubMed] [Google Scholar]
  • Karaiskos I, Giamarellou H, (2014) Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother 15: 1351–1370 [CrossRef] [PubMed] [Google Scholar]
  • Nordmann P, Dortet L, Poirel L, (2012) Carbapenem-resistance in Enterobacteriaceae: here is the storm! Trends Mol Med 18: 263–272 [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.